vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and INTERFACE INC (TILE). Click either name above to swap in a different company.
INTERFACE INC is the larger business by last-quarter revenue ($349.4M vs $183.1M, roughly 1.9× Amphastar Pharmaceuticals, Inc.). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs 7.0%, a 6.4% gap on every dollar of revenue. On growth, INTERFACE INC posted the faster year-over-year revenue change (4.3% vs -1.8%). INTERFACE INC produced more free cash flow last quarter ($28.6M vs $24.6M). Over the past eight quarters, INTERFACE INC's revenue compounded faster (9.8% CAGR vs 3.2%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Interface, Inc., headquartered in Atlanta, Georgia, is a global manufacturer of commercial flooring. The company sells modular carpet tiles, luxury vinyl tile, and Nora brand rubber flooring.
AMPH vs TILE — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $349.4M |
| Net Profit | $24.4M | $24.4M |
| Gross Margin | 46.8% | 38.6% |
| Operating Margin | 19.4% | 10.1% |
| Net Margin | 13.3% | 7.0% |
| Revenue YoY | -1.8% | 4.3% |
| Net Profit YoY | -35.7% | 12.1% |
| EPS (diluted) | $0.51 | $0.41 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $349.4M | ||
| Q3 25 | $191.8M | $364.5M | ||
| Q2 25 | $174.4M | $375.5M | ||
| Q1 25 | $170.5M | $297.4M | ||
| Q4 24 | $186.5M | $335.0M | ||
| Q3 24 | $191.2M | $344.3M | ||
| Q2 24 | $182.4M | $346.6M | ||
| Q1 24 | $171.8M | $289.7M |
| Q4 25 | $24.4M | $24.4M | ||
| Q3 25 | $17.4M | $46.1M | ||
| Q2 25 | $31.0M | $32.6M | ||
| Q1 25 | $25.3M | $13.0M | ||
| Q4 24 | $38.0M | $21.8M | ||
| Q3 24 | $40.4M | $28.4M | ||
| Q2 24 | $37.9M | $22.6M | ||
| Q1 24 | $43.2M | $14.2M |
| Q4 25 | 46.8% | 38.6% | ||
| Q3 25 | 51.4% | 39.4% | ||
| Q2 25 | 49.6% | 39.4% | ||
| Q1 25 | 50.0% | 37.3% | ||
| Q4 24 | 46.5% | 36.5% | ||
| Q3 24 | 53.3% | 37.1% | ||
| Q2 24 | 52.2% | 35.4% | ||
| Q1 24 | 52.4% | 38.1% |
| Q4 25 | 19.4% | 10.1% | ||
| Q3 25 | 13.2% | 14.6% | ||
| Q2 25 | 24.2% | 13.9% | ||
| Q1 25 | 21.9% | 7.8% | ||
| Q4 24 | 24.2% | 8.8% | ||
| Q3 24 | 29.8% | 12.3% | ||
| Q2 24 | 30.3% | 11.0% | ||
| Q1 24 | 27.9% | 8.4% |
| Q4 25 | 13.3% | 7.0% | ||
| Q3 25 | 9.0% | 12.7% | ||
| Q2 25 | 17.8% | 8.7% | ||
| Q1 25 | 14.8% | 4.4% | ||
| Q4 24 | 20.4% | 6.5% | ||
| Q3 24 | 21.1% | 8.3% | ||
| Q2 24 | 20.8% | 6.5% | ||
| Q1 24 | 25.1% | 4.9% |
| Q4 25 | $0.51 | $0.41 | ||
| Q3 25 | $0.37 | $0.78 | ||
| Q2 25 | $0.64 | $0.55 | ||
| Q1 25 | $0.51 | $0.22 | ||
| Q4 24 | $0.74 | $0.38 | ||
| Q3 24 | $0.78 | $0.48 | ||
| Q2 24 | $0.73 | $0.38 | ||
| Q1 24 | $0.81 | $0.24 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $71.3M |
| Total DebtLower is stronger | $608.7M | $181.6M |
| Stockholders' EquityBook value | $788.8M | $640.7M |
| Total Assets | $1.6B | $1.2B |
| Debt / EquityLower = less leverage | 0.77× | 0.28× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $71.3M | ||
| Q3 25 | $276.2M | $187.4M | ||
| Q2 25 | $231.8M | $121.7M | ||
| Q1 25 | $236.9M | $97.8M | ||
| Q4 24 | $221.6M | $99.2M | ||
| Q3 24 | $250.5M | $115.6M | ||
| Q2 24 | $217.8M | $94.2M | ||
| Q1 24 | $289.6M | $89.8M |
| Q4 25 | $608.7M | $181.6M | ||
| Q3 25 | $608.6M | $307.8M | ||
| Q2 25 | $607.7M | $304.4M | ||
| Q1 25 | $603.9M | $302.9M | ||
| Q4 24 | $601.6M | $302.8M | ||
| Q3 24 | $596.4M | $337.9M | ||
| Q2 24 | $586.9M | $387.6M | ||
| Q1 24 | $594.0M | $391.8M |
| Q4 25 | $788.8M | $640.7M | ||
| Q3 25 | $776.7M | $621.0M | ||
| Q2 25 | $757.5M | $575.0M | ||
| Q1 25 | $751.3M | $513.1M | ||
| Q4 24 | $732.3M | $489.1M | ||
| Q3 24 | $727.7M | $501.6M | ||
| Q2 24 | $713.3M | $451.2M | ||
| Q1 24 | $672.4M | $428.5M |
| Q4 25 | $1.6B | $1.2B | ||
| Q3 25 | $1.7B | $1.3B | ||
| Q2 25 | $1.6B | $1.3B | ||
| Q1 25 | $1.6B | $1.2B | ||
| Q4 24 | $1.6B | $1.2B | ||
| Q3 24 | $1.5B | $1.2B | ||
| Q2 24 | $1.5B | $1.2B | ||
| Q1 24 | $1.6B | $1.2B |
| Q4 25 | 0.77× | 0.28× | ||
| Q3 25 | 0.78× | 0.50× | ||
| Q2 25 | 0.80× | 0.53× | ||
| Q1 25 | 0.80× | 0.59× | ||
| Q4 24 | 0.82× | 0.62× | ||
| Q3 24 | 0.82× | 0.67× | ||
| Q2 24 | 0.82× | 0.86× | ||
| Q1 24 | 0.88× | 0.91× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $49.3M |
| Free Cash FlowOCF − Capex | $24.6M | $28.6M |
| FCF MarginFCF / Revenue | 13.4% | 8.2% |
| Capex IntensityCapex / Revenue | 4.5% | 5.9% |
| Cash ConversionOCF / Net Profit | 1.35× | 2.02× |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $121.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $49.3M | ||
| Q3 25 | $52.6M | $76.7M | ||
| Q2 25 | $35.6M | $30.1M | ||
| Q1 25 | $35.1M | $11.7M | ||
| Q4 24 | $29.0M | $38.0M | ||
| Q3 24 | $60.0M | $76.2M | ||
| Q2 24 | $69.1M | $21.5M | ||
| Q1 24 | $55.3M | $12.6M |
| Q4 25 | $24.6M | $28.6M | ||
| Q3 25 | $47.2M | $66.1M | ||
| Q2 25 | $25.0M | $22.8M | ||
| Q1 25 | $24.4M | $4.3M | ||
| Q4 24 | $16.6M | $24.4M | ||
| Q3 24 | $46.2M | $69.7M | ||
| Q2 24 | $63.1M | $12.0M | ||
| Q1 24 | $46.5M | $8.6M |
| Q4 25 | 13.4% | 8.2% | ||
| Q3 25 | 24.6% | 18.1% | ||
| Q2 25 | 14.3% | 6.1% | ||
| Q1 25 | 14.3% | 1.4% | ||
| Q4 24 | 8.9% | 7.3% | ||
| Q3 24 | 24.1% | 20.3% | ||
| Q2 24 | 34.6% | 3.5% | ||
| Q1 24 | 27.1% | 3.0% |
| Q4 25 | 4.5% | 5.9% | ||
| Q3 25 | 2.8% | 2.9% | ||
| Q2 25 | 6.1% | 2.0% | ||
| Q1 25 | 6.3% | 2.5% | ||
| Q4 24 | 6.7% | 4.1% | ||
| Q3 24 | 7.2% | 1.9% | ||
| Q2 24 | 3.3% | 2.8% | ||
| Q1 24 | 5.1% | 1.4% |
| Q4 25 | 1.35× | 2.02× | ||
| Q3 25 | 3.03× | 1.66× | ||
| Q2 25 | 1.15× | 0.93× | ||
| Q1 25 | 1.39× | 0.90× | ||
| Q4 24 | 0.76× | 1.75× | ||
| Q3 24 | 1.48× | 2.68× | ||
| Q2 24 | 1.82× | 0.95× | ||
| Q1 24 | 1.28× | 0.89× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
TILE
| AMS | $205.9M | 59% |
| EAAA | $143.5M | 41% |
